SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors
Redox Biology · 2024-10 · 76 · 103304
DOI: 10.1016/j.redox.2024.103304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Redox Biology, 2024-10. Verfasst von Yingshu Cui und 15 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA, Beijing, 100853, China; Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, 10007…. Hauptthemen laut MEDLINE: Ferroptosis, Amino Acid Transport System y+, Cyclin-Dependent Kinase 4, Breast Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Aerospace Science Foundation of China.
Abstract (Originalsprache)
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6 inhibitors) can significantly extend tumor response in patients with metastatic luminal A breast cancer, yet intrinsic and acquired resistance remains a prevalent issue. Understanding the molecular features of CDK4/6 inhibitor sensitivity and the potential efficacy of their combination with novel targeted cell death inducers may lead to improved patient outcomes. Herein, we demonstrate that ferroptosis, a form of regulated cell death driven by iron-dependent phospholipid peroxidation, partly underpins the efficacy of CDK4/6 inhibitors. Mechanistically, CDK4/6 inhibitors downregulate the cystine transporter SLC7A11 by inhibiting SP1 binding to the SLC7A11 promoter region. Furthermore, SLC7A11 is identified as critical for the intrinsic sensitivity of luminal A breast cancer to CDK4/6 inhibitors. Both genetic and pharmacological inhibition of SP1 or SLC7A11 enhances cell sensitivity to CDK4/6 inhibitors and synergistically inhibits luminal A breast cancer growth when combined with CDK4/6 inhibitors in vitro and in vivo. Our data highlight the potential of targeting SLC7A11 in combination with CDK4/6 inhibitors, supporting further investigation of combination therapy in luminal A breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School of Chinese PLA, Beijing, 100853, China; Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, 100071, China.
- Medical School of Chinese PLA, Beijing, 100853, China.
- Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, 100071, China.
- Department of General Surgery, Peking University First Hospital, Beijing, 100034, China.
- Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, 100071, China.
- State Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Haikou, 570100, China. Electronic address: zhouff@hainanu.edu.cn.
Förderung
- National Aerospace Science Foundation of China
Zitieren
APA
Cui, Y., Li, Y., Xu, Y., Liu, X., Kang, X., Zhu, J., Long, S., Han, Y., Xue, C., Sun, Z., Du, Y., Hu, J., Pan, L., Zhou, F., Xu, X., & Li, X. (2024). SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors. Redox Biology, 76, 103304. https://doi.org/10.1016/j.redox.2024.103304
Vancouver
Cui Y, Li Y, Xu Y, Liu X, Kang X, Zhu J, et al. SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors. Redox Biology. 2024;76:103304. doi:10.1016/j.redox.2024.103304
BibTeX
@article{Cui2024,
author = {Cui, Yingshu and Li, Yi and Xu, Yuanyuan and Liu, Xinxin and Kang, Xiaofeng and Zhu, Junwen and Long, Shan and Han, Yuchen and Xue, Chunyuan and Sun, Zhijia and Du, Yimeng and Hu, Jia and Pan, Lu and Zhou, Feifan and Xu, Xiaojie and Li, Xiaosong},
title = {SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors},
journal = {Redox Biology},
year = {2024},
volume = {76},
pages = {103304},
doi = {10.1016/j.redox.2024.103304}
}
EUVIMED